Cancer Invest. 2007 Dec;25(8):715-9.

Macrophage migration inhibitory factor in cancer.

Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F, Dalay N.

Source

Department of Basic Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. yasasever@yahoo.com

Abstract

The objective of this study was to investigate the expression of macrophage migration inhibitory factor (MIF) in patients with colorectal cancer (GIS) and malignant melanoma (MM). The study group consists of pathologically verified colorectal cancer (n = 63) and malignant melanoma (n = 65) patients and healthy controls (n = 25). Serum MIF concentrations were determined by enzyme-linked immunosorbent assay. Serum values of the patients were significantly higher than the controls (p < 0.001 for GIS, p = 0.032 for MM). Diagnostic sensitivity and specificity were calculated for MIF for colorectal and malignant melanoma. The results demonstrate that colorectal cancer express and secrete large amounts of MIF.

PMID:: 18058468; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Related citations

The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. [Pathol Oncol Res. 2008]
The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.
Camlica H, Duranyildiz D, Oguz H, Oral EN, Yasasever V. Pathol Oncol Res. 2008 Mar; 14(1):79-83. Epub 2008 Mar 18.
Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. [Am J Clin Pathol. 2008]
Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas.
Lee H, Rhee H, Kang HJ, Kim HS, Min BS, Kim NK, Kim H. Am J Clin Pathol. 2008 May; 129(5):772-9.
Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer. [Dig Dis Sci. 2005]
Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B, Szmitkowski M, Wereszczyńska-Siemiatkowska U, Okulczyk B. Dig Dis Sci. 2005 Jun; 50(6):1019-24.
Review [Serum markers for breast and colorectal cancers. Working group reunited by the National Health Agency for Accreditation and Evaluation (NHAAE)]. [Gastroenterol Clin Biol. 1998]
Review [Serum markers for breast and colorectal cancers. Working group reunited by the National Health Agency for Accreditation and Evaluation (NHAAE)].
Mlika-Cabanne N, Bellet D. Gastroenterol Clin Biol. 1998 Apr; 22(4):442-57.
Review Molecular and biochemical markers in colorectal cancer. [Ann Oncol. 2002]
Review Molecular and biochemical markers in colorectal cancer.
McDermott U, Longley DB, Johnston PG. Ann Oncol. 2002; 13 Suppl 4:235-45.

See reviews... See all...

Cited by 3 PubMed Central articles

Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis. [BMC Res Notes. 2011]
Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis.
Vera PL, Meyer-Siegler KL. BMC Res Notes. 2011 Oct 11; 4:395. Epub 2011 Oct 11.
Review Macrophage migration inhibitory factor (MIF): a promising biomarker. [Drug News Perspect. 2010]
Review Macrophage migration inhibitory factor (MIF): a promising biomarker.
Grieb G, Merk M, Bernhagen J, Bucala R. Drug News Perspect. 2010 May; 23(4):257-64.
Review CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. [World J Gastroenterol. 2009]
Review CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.
Beswick EJ, Reyes VE. World J Gastroenterol. 2009 Jun 21; 15(23):2855-61.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Macrophage migration inhibitory factor in cancer.
Macrophage migration inhibitory factor in cancer.
Cancer Invest. 2007 Dec ;25(8):715-9.

PubMed
Comparison of outcomes among patients randomized to warfarin therapy according t...
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
Arch Intern Med. 2007 Feb 12 ;167(3):239-45.

PubMed
Antiarrhythmic properties of acetaminophen in the dog.
Antiarrhythmic properties of acetaminophen in the dog.
Exp Biol Med (Maywood). 2007 Oct ;232(9):1245-52.

PubMed
Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure ...
Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
Int J Obes (Lond). 2008 May ;32(5):863-70. Epub 2008 Feb 5 .

PubMed
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibod...
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2010 Feb ;51(2):228-35.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Macrophage migration inhibitory factor in cancer.

Source

Abstract

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Related citations

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information